Pharma · Private company
Boehringer Ingelheim
Track this companyFree. Adds Boehringer Ingelheim to your Dealase workspace and tells you when its record changes.
Clinical trials2525 recruiting or active
Pipeline programs49From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline49
- atezolizumabPhase 3 · Small Cell Lung Cancer (SCLC)ClinicalTrials.gov · fetched Nov 12, 2026
- AtezolizumabPhase 3 · Non-small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- BI 764198Phase 3 · Focal Segmental GlomerulosclerosisClinicalTrials.gov · fetched Nov 12, 2026
- carboplatinPhase 3 · Small Cell Lung Cancer (SCLC)ClinicalTrials.gov · fetched Nov 12, 2026
- CarboplatinPhase 3 · Extrapulmonary Neuroendocrine Cancer (epNEC)ClinicalTrials.gov · fetched Nov 12, 2026
- DurvalumabPhase 3 · Non-small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- EmpagliflozinPhase 3 · Chronic Kidney DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- etoposidePhase 3 · Small Cell Lung Cancer (SCLC)ClinicalTrials.gov · fetched Nov 12, 2026
- EtoposidePhase 3 · Extrapulmonary Neuroendocrine Cancer (epNEC)ClinicalTrials.gov · fetched Nov 12, 2026
- NerandomilastPhase 3 · Fibrosing Interstitial Lung DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- NivolumabPhase 3 · Non-small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- obrixtamigPhase 3 · Small Cell Lung Cancer (SCLC)ClinicalTrials.gov · fetched Nov 12, 2026
- ObrixtamigPhase 3 · Extrapulmonary Neuroendocrine Cancer (epNEC)ClinicalTrials.gov · fetched Nov 12, 2026
- PembrolizumabPhase 3 · Non-small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- SurvodutidePhase 3 · ObesityClinicalTrials.gov · fetched Nov 12, 2026
- Ventana DLL3 RxDx assayPhase 3 · Extrapulmonary Neuroendocrine Cancer (epNEC)ClinicalTrials.gov · fetched Nov 12, 2026
- verducatibPhase 3 · BronchiectasisClinicalTrials.gov · fetched Nov 12, 2026
- VerducatibPhase 3 · Chronic Obstructive Pulmonary DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- ZongertinibPhase 3 · Non-small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- BI 3810477Phase 2 · Idiopathic Pulmonary FibrosisClinicalTrials.gov · fetched Nov 12, 2026
- BI 765423Phase 2 · Idiopathic Pulmonary FibrosisClinicalTrials.gov · fetched Nov 12, 2026
- CapecitabinePhase 2 · Metastatic Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- CarboplatinPhase 2 · Extensive-stage Small Cell Lung CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- EtoposidePhase 2 · Extensive-stage Small Cell Lung CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- mFOLFOX6Phase 2 · Metastatic Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- ObrixtamigPhase 2 · Extensive-stage Small Cell Lung CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- PumitamigPhase 2 · Extensive-stage Small Cell Lung CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- TrastuzumabPhase 2 · Metastatic Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- Trastuzumab deruxtecanPhase 2 · Metastatic Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- Trastuzumab emtansinePhase 2 · Metastatic Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- ZongertinibPhase 2 · Solid TumoursClinicalTrials.gov · fetched Nov 12, 2026
- ZongertinibPhase 2 · Metastatic Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- BI 1701963Phase 1 · Solid Tumors, KRAS MutationClinicalTrials.gov · fetched Nov 12, 2026
- BI 1703880Phase 1 · Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- BI 1823911Phase 1 · Solid Tumors, KRAS MutationClinicalTrials.gov · fetched Nov 12, 2026
- BI 3810944Phase 1 · Solid TumoursClinicalTrials.gov · fetched Nov 12, 2026
- BI 3819026Phase 1 · Advanced Solid CancerClinicalTrials.gov · fetched Nov 12, 2026
- BI 3968621Phase 1 · Advanced Solid TumourClinicalTrials.gov · fetched Nov 12, 2026
- BI 4015092Phase 1 · Advanced or Metastatic Solid Tumors With KRAS G12D MutationClinicalTrials.gov · fetched Nov 12, 2026
- BI 765179Phase 1 · NeoplasmsClinicalTrials.gov · fetched Nov 12, 2026
- CetuximabPhase 1 · Advanced or Metastatic Solid Tumors With KRAS G12D MutationClinicalTrials.gov · fetched Nov 12, 2026
- ezabenlimabPhase 1 · Advanced Solid TumourClinicalTrials.gov · fetched Nov 12, 2026
- EzabenlimabPhase 1 · NeoplasmsClinicalTrials.gov · fetched Nov 12, 2026
- EzabenlimabPhase 1 · Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- Ezabenlimab (BI 754091)Phase 1 · Advanced Solid CancerClinicalTrials.gov · fetched Nov 12, 2026
- MidazolamPhase 1 · Solid Tumors, KRAS MutationClinicalTrials.gov · fetched Nov 12, 2026
- Obrixtamig - parenteral 1Phase 1 · Small Cell Lung Carcinoma and Other Neuroendocrine Neoplasms Expressing DLL3ClinicalTrials.gov · fetched Nov 12, 2026
- Obrixtamig - parenteral 2Phase 1 · Small Cell Lung Carcinoma and Other Neuroendocrine Neoplasms Expressing DLL3ClinicalTrials.gov · fetched Nov 12, 2026
- PembrolizumabPhase 1 · NeoplasmsClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials25
- The AIRWARD Study: A Study to Test Whether Verducatib Helps People With Chronic Obstructive Pulmonary DiseasePHASE3 · NOT_YET_RECRUITING · started Mar 10, 2027ClinicalTrials.gov NCT07907991 · fetched Nov 12, 2026
- A Study to Learn How Well People With Bronchiectasis Tolerate Continued Treatment With Verducatib After Earlier Studies (AIRTIVITY®-ON)PHASE3 · NOT_YET_RECRUITING · started Jan 11, 2027ClinicalTrials.gov NCT07915219 · fetched Nov 12, 2026
- A Study of BI 4015092, Alone or in Combination With Other Cancer Treatment, in Patients With Advanced Cancer That Has a KRAS G12D MutationPHASE1 · NOT_YET_RECRUITING · started Dec 7, 2026ClinicalTrials.gov NCT07926334 · fetched Nov 12, 2026
- A Study to Test Whether BI 3810477 Helps People With Idiopathic Pulmonary Fibrosis When Taken With or Without Standard TreatmentPHASE2 · NOT_YET_RECRUITING · started Nov 13, 2026ClinicalTrials.gov NCT07926321 · fetched Nov 12, 2026
- A Study to Test Different Doses of BI 3968621 When Given Alone or With Ezabenlimab in Patients With Advanced CancerPHASE1 · RECRUITING · started Nov 10, 2026ClinicalTrials.gov NCT07851103 · fetched Nov 12, 2026
- ELEVATE-LIVER: A Study to Test Whether Survodutide Helps Improve Heart Structure and Function in People With Overweight or Obesity and Fatty Liver DiseasePHASE3 · NOT_YET_RECRUITING · started Nov 2, 2026ClinicalTrials.gov NCT07850063 · fetched Nov 12, 2026
- SYNCHRONIZE®-HERA: A Study to Test Whether Survodutide Helps Women Who Are Living With Overweight or Obesity and Are Going Through or Have Finished Menopause, to Lose WeightPHASE3 · NOT_YET_RECRUITING · started Oct 31, 2026ClinicalTrials.gov NCT07850050 · fetched Nov 12, 2026
- A Study to Test Obrixtamig in Combination With Pumitamig in People With Advanced Small Cell Lung Cancer (Dareon®-Rosetta35)PHASE1_PHASE2 · RECRUITING · started Oct 1, 2026ClinicalTrials.gov NCT07843940 · fetched Nov 12, 2026
- A Study to Find Out How Nerandomilast is Tolerated, Handled by the Body, and if it Helps Children and Adolescents With Interstitial Lung Disease (FIBRONEER-chILD)PHASE3 · RECRUITING · started Jul 21, 2026ClinicalTrials.gov NCT07366034 · fetched Nov 12, 2026
- DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard ChemotherapyPHASE3 · RECRUITING · started Jul 10, 2026ClinicalTrials.gov NCT07544654 · fetched Nov 12, 2026
- A Study in People With Advanced Cancer to Test How Well Different Doses of BI 3819026 Are Tolerated When Taken Alone and Together With EzabenlimabPHASE1 · RECRUITING · started May 1, 2026ClinicalTrials.gov NCT07607678 · fetched Nov 12, 2026
- DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard ChemoimmunotherapyPHASE3 · RECRUITING · started Apr 13, 2026ClinicalTrials.gov NCT07472517 · fetched Nov 12, 2026
- A Study of BI 3810944 in Patients With Advanced CancerPHASE1 · RECRUITING · started Feb 24, 2026ClinicalTrials.gov NCT07224425 · fetched Nov 12, 2026
- A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS)PHASE3 · RECRUITING · started Feb 16, 2026ClinicalTrials.gov NCT07220083 · fetched Nov 12, 2026
- Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD MutationsPHASE3 · RECRUITING · started Jan 16, 2026ClinicalTrials.gov NCT07195695 · fetched Nov 12, 2026
- A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids)PHASE3 · ACTIVE_NOT_RECRUITING · started Dec 9, 2025ClinicalTrials.gov NCT07107945 · fetched Nov 12, 2026
- A Study to Find Out Whether BI 765423 Has an Effect on Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) With or Without Standard TreatmentPHASE2 · ACTIVE_NOT_RECRUITING · started Nov 13, 2025ClinicalTrials.gov NCT07036523 · fetched Nov 12, 2026
- A Study to Test Whether Spesolimab Helps People With a Skin Condition Called Pyoderma GangrenosumPHASE3 · RECRUITING · started Feb 5, 2025ClinicalTrials.gov NCT06624670 · fetched Nov 12, 2026
- Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 AlterationsPHASE2 · RECRUITING · started Oct 11, 2024ClinicalTrials.gov NCT06581432 · fetched Nov 12, 2026
- Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has SpreadPHASE1_PHASE2 · RECRUITING · started Jun 28, 2024ClinicalTrials.gov NCT06324357 · fetched Nov 12, 2026
- Safety and Efficacy of Empagliflozin in HemodialysisPHASE2 · ACTIVE_NOT_RECRUITING · started Jan 31, 2024ClinicalTrials.gov NCT05786443 · fetched Nov 12, 2026
- A Study to Test How Different Doses of BI 1703880 in Combination With Ezabenlimab Are Tolerated in People With Different Types of Advanced Cancer (Solid Tumours)PHASE1 · RECRUITING · started Feb 24, 2023ClinicalTrials.gov NCT05471856 · fetched Nov 12, 2026
- A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck CancerPHASE1 · ACTIVE_NOT_RECRUITING · started Oct 18, 2021ClinicalTrials.gov NCT04958239 · fetched Nov 12, 2026
- A Study to Test Different Doses of BI 1823911 Alone and Combined With Other Medicines in People With Different Types of Advanced Cancer With KRAS MutationPHASE1 · ACTIVE_NOT_RECRUITING · started Sep 9, 2021ClinicalTrials.gov NCT04973163 · fetched Nov 12, 2026
- A Study to Test Different Doses of Obrixtamig in Patients With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3PHASE1 · ACTIVE_NOT_RECRUITING · started Jul 29, 2020ClinicalTrials.gov NCT04429087 · fetched Nov 12, 2026